Ann: Investor Webinar Presentation, page-42

Qbrexza hasn’t had commercial success, but there’s facts from Qbrexza’s history that support BOT’s claims for the need for, and market, of a hyperhydrosis treatment

- 6 Pharmaceutical companies invested in Qbrexza. (Ownership of Qbrexza from 2005 Connetics > 2006 Stiefel > 2009 GlaxoSmithKline (shelved due to concerns over the safety of Glycopyrronium) > 2014 Dermira (FDA approval June 2018) > 2020 Eli Lilly > 2021 Journey Medical Corp)

- The FDA approved Qbrexza

-Within a year of FDA approval 80% of commercial lives had insurance coverage for Qbrexza

-There was growth in the amount of prescriptions over the first year 14,500 Q4 2018 > 23,559 prescriptions in Q1 2019 > 28,609 prescriptions in Q2 2019 > 32,646 prescripti- ons in Q3 2019

And I think that it is worth mentioning that Dermira’s advertising campaign for the first year was unbranded, they spent tens of millions of dollars on the ‘know your sweat’ campaign to educate/change public perception because the public didn’t consider hyperhidrosis a medical condition, and therefore weren’t seeking medical treatment. Their branded ad’s started in May 2019.